SNPMiner Trials (Home Page)
Report for Mutation A2144G
 Developed by Shray Alag, 2020.
SNP Clinical Trial Gene 
There is one clinical trial. 
Clinical Trials
      The goal of this trial is to compare the non-inferiority efficacy and safety of two different
      treatment schemes: pantoprazole 80 mg + levofloxacin 500 mg + azithromycin 500 mg once daily
      (PLA, test) vs. clarithromycin 500 mg + lansoprazole 30 mg + amoxicillin 1 g twice daily
      (CLA, reference), each during 10 days, over Helicobacter Pylori (HP) eradication. Both
      schemes will be tested in treatment-naive patients, with biopsy-based diagnosis for HP
      infection. One month after finishing each treatment, C13-urea breath testing will be required
      to verify HP eradication. Biopsies will also be taken to identify Clarithromycin-resistance
      mutations in HP strains by fluorescence in situ hybridization (FISH).
    
NCT02726269  Helicobacter Pylori Gastritis  Drug: CLA (Clarithro+Lanso+Amoxi)  Drug: PLA (Panto+Levoflox+Azithro) 
The probe for H. pylori identification (Hpy 1)
      (5'CACACCTGACTGACTATCCCG-3') will be labeled with fluorescein isothiocyanate (FITC) that
      provides a green signal, and the probes that detect the three most prevalent
      clarithromycin-resistance mutations (ClaR1 (A2143G) 5'CGGGGTCTTCCCGTCTt-3', ClaR2 (A2144G)
      5'CGGGGCTCTCCGTCTT-3', and ClaR3 (A21443C) 5-CGGGGTCTTGCCGTCTT-3') will be labeled with red
      fluorochrome (Cy3). --- A2143G ---  --- A2144G --- 
  Primary Outcomes 
 Measure: HP eradication rate calculated from negative 13C-urea breath tests.
 Time: Four weeks after the end of the allocated treatment.
  Secondary Outcomes 
 Measure: Determine the frequency of Clarithromycin-resistance mutations by fluorescence in situ hybridization (FISH).
 Time: Within a month after taking gastric endoscopy biopsy to confirm the diagnosis of HP infection.
 Measure: Compare the proportion of Clarithromycin-resistance mutations determined by FISH with the HP eradication rate calculated.
 Time: A week after both proportions are calculated.
  Other Outcomes 
 Measure: Percentage and type of Adverse Events (AEs) and Serious Adverse Events (SAEs) in each group (PLA vs CLA).
 Time: Up to a month after the end of both treatments.
 Measure: Proportion of treatments prematurely suspended due to AEs or SAEs in each group (PLA vs CLA).
 Time: Within ten days after each treatment is randomly allocated.
HPO Nodes
Genes 16
TTC37  RIPK1  FAS  IL1B  CASP10  SKIV2L  IL1RN  FAS  FASLG  FOXP3  RASGRP1  LRBA  KRAS  AIRE  PRKCD  CDH1   hr>